Health Catalyst, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Health Catalyst, Inc. on August 11, 2020. The filing primarily discloses the entry into an acquisition agreement to purchase Vitalware, LLC, a Delaware limited liability company.
Key Financial Metrics and Transaction Details
The filing details a specific corporate transaction rather than periodic financial performance metrics such as revenue or cash flow.
- Acquisition Target: Vitalware, LLC.
- Aggregate Purchase Price: Approximately $120 million.
- Consideration Structure:
- Initial Equity: 1,487,210 shares of Health Catalyst Common Stock valued at $33.62 per share (based on a 35-day average trading price ending August 7, 2020).
- Potential Earnout: Up to $30 million in additional Common Stock contingent on performance targets met by March 31, 2021.
- Expected Closing: Third or fourth quarter of 2020, subject to customary closing conditions.
Material Changes
The material change reported is the strategic expansion through the acquisition of Vitalware. The transaction involves the issuance of unregistered equity securities pursuant to Section 4(a)(2) of the Securities Act of 1933 and/or Rule 506 of Regulation D. No public offering or solicitation is being conducted.
Outlook, Risks, and Management Commentary
Management expects the transaction to close in late 2020. The filing includes a cautionary note regarding forward-looking statements, highlighting risks that could cause actual results to differ materially from expectations. Key risks include:
- Adverse and unpredictable macro-economic conditions.
- Risks related to the successful closing of the transaction.
- Challenges associated with the integration of the two companies.
Health Catalyst disclaims any obligation to update these forward-looking statements.
Investor Verification Checklist
- Verify the final closing date of the Vitalware acquisition against the projected third or fourth quarter of 2020 timeline.
- Monitor the performance targets for the $30 million earnout provision to be calculated as of March 31, 2021.
- Review the attached press release (Exhibit 99.1) and investor presentation (Exhibit 99.2) for strategic rationale and integration plans.
- Confirm the impact of the 1,487,210 new shares on existing shareholder dilution upon closing.